A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer
Drug Delivery and Translational Research · 2025-01 · 15 (1) · 102-133
DOI: 10.1007/s13346-024-01648-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Delivery and Translational Research, online erschienen am 17.06.2024. Verfasst von Anjali Bisht und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Quality Assurance, ISF College Pharmacy, GT Road, Moga, 142001, Punjab, India. Hauptthemen laut MEDLINE: Doxorubicin, Breast Neoplasms. Die Arbeit wurde bisher 186-mal zitiert (Crossref) und nennt 128 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Doxorubicin is a key treatment for breast cancer, but its effectiveness often comes with significant side effects. Its actions include DNA intercalation, topoisomerase II inhibition, and reactive oxygen species generation, leading to DNA damage and cell death. However, it can also cause heart problems and low blood cell counts. Current trials aim to improve doxorubicin therapy by adjusting doses, using different administration methods, and combining it with targeted treatments or immunotherapy. Nanoformulations show promise in enhancing doxorubicin's effectiveness by improving drug delivery, reducing side effects, and overcoming drug resistance. This review summarizes recent progress and difficulties in using doxorubicin for breast cancer, highlighting its mechanisms, side effects, ongoing trials, and the potential impact of nanoformulations. Understanding these different aspects is crucial in optimizing doxorubicin's use and improving outcomes for breast cancer patients. This review examines the toxicity of doxorubicin, a drug used in breast cancer treatment, and discusses strategies to mitigate adverse effects, such as cardioprotective agents and liposomal formulations. It also discusses clinical trials evaluating doxorubicin-based regimens, the evolving landscape of combination therapies, and the potential of nanoformulations to optimize delivery and reduce systemic toxicity. The review also discusses the potential of liposomes, nanoparticles, and polymeric micelles to enhance drug accumulation within tumor tissues while sparing healthy organs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Quality Assurance, ISF College Pharmacy, GT Road, Moga, 142001, Punjab, India.
- Institute of Pharmaceutical Research, GLA University, 17 km Stone, NH-2, Chaumuhan, Mathura, 281406, UP, India.
- Department of Pharmaceutical Chemistry, ISF College Pharmacy, GT Road, Moga, 142001, Punjab, India.
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India.
- Department of Pharmaceutics, ISF College of Pharmacy, GT Road, Moga, 142001, Punjab, India. bdkurmi@gmail.com.
ORCID-Profile: Balak Das Kurmi
Förderung
- Indian Council of Medical Research
Zitieren
APA
Bisht, A., Avinash, D., Sahu, K. K., Patel, P., Das Gupta, G., & Kurmi, B. D. (2025). A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Delivery and Translational Research, 15(1), 102-133. https://doi.org/10.1007/s13346-024-01648-0
Vancouver
Bisht A, Avinash D, Sahu KK, Patel P, Das Gupta G, Kurmi BD. A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer. Drug Delivery and Translational Research. 2025;15(1):102-133. doi:10.1007/s13346-024-01648-0
BibTeX
@article{Bisht2025,
author = {Bisht, Anjali and Avinash, Dubey and Sahu, Kantrol Kumar and Patel, Preeti and Das Gupta, Ghanshyam and Kurmi, Balak Das},
title = {A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer},
journal = {Drug Delivery and Translational Research},
year = {2025},
volume = {15},
number = {1},
pages = {102--133},
doi = {10.1007/s13346-024-01648-0}
}
EUVIMED